TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06285045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roujin Formula
Description: 48 eligible participants with FMS of blood deficiency and liver depression syndrome were selected and randomly divided into treatment group(n=24)and control group(n=24). The treatment group was given Roujin Foumula 150mL,twice a day; The control group was given Roujin Foumula placebo 150mL,twice a day,the study period was 8 weeks. The evaluation points were 0 weeks,4 weeks,and 8 weeks of treatment,and follow-up to 12 weeks. To evaluate the effect changes before and after treatment,FIQR score、VAS score、PSQI score、BDI score and SF-36 PCS、MCS score were used as secondary efficacy evaluation indexes. SPSS23.0 was used to analyze the data.
Study: NCT01724229

Intervention type: DRUG
Group type: OTHER
Intervention: Kendall Body Wash & Shampoo; Moisture Barrier Cream; 2-in-1 Cleanser; Antifungal Cream
Study: NCT01668160

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bead placement during revision hip replacement surgery
Description: Tantalum beads will be placed in the surrounding pelvic and femoral bone and the polyethylene component during surgical treatment of failed primary THA components
Study: NCT04190823

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC98
Description: Participants will be allocated to one of the following dose groups: 0.003, 0.03, 0.3, 2.5, 5.0, 10.0, 15.0 and 20.0 mg/kg, and receive one treatment of RC98 followed by 28 days of dose limited toxicity (DLT) observation period.
Study: NCT03027193

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA HAV
Description: The MVA HAV vaccine consists of the replication deficient modified vaccinia virus Ankara (MVA) containing the Mycobacterium avium subspecies paratuberculosis (MAP) antigens.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA HAV
Description: The MVA HAV vaccine consists of the replication deficient modified vaccinia virus Ankara (MVA) containing the Mycobacterium avium subspecies paratuberculosis (MAP) antigens.
Study: NCT04324788

Intervention type: OTHER
Intervention: Group 1
Description: The patients will be asked to go up and down 9-step stair with the highest speed they can make.

Intervention type: OTHER
Intervention: Group 2
Description: The patients will be asked to go up and down 9-step stair with the highest speed they can make.
Study: NCT01373918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intralipid
Description: The subject will receive 1 g/kg/d of the standard intravenous fat emulsion while receiving Parenteral Nutrition until discharge from the hospital, death or 100 days of life, whichever comes first.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intralipid
Description: The subject will receive 3 g/kg/d of the standard intravenous fat emulsion while receiving Parenteral Nutrition until discharge from the hospital, death or 100 days of life, whichever comes first.
Study: NCT02970396

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: self-management

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: self-management
Study: NCT04834141

Intervention type: OTHER
Intervention: FlexiCurve ruler method to assess thoracic kyphosis angle
Description: The determination that the effect of thoracic kyphosis posture on trunk biomechanical alignment may be related to balance may contribute to new treatment recommendations in this area. The aim of this study is to investigate whether the thoracic kyphosis posture has an effect on static balance.

Intervention type: OTHER
Intervention: FlexiCurve ruler method to assess thoracic kyphosis angle
Description: The determination that the effect of thoracic kyphosis posture on trunk biomechanical alignment may be related to balance may contribute to new treatment recommendations in this area. The aim of this study is to investigate whether the thoracic kyphosis posture has an effect on static balance.
Study: NCT00746343

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IRRI
Description: Subjects will remain in their assigned treatment condition for 24 months. IRRI subjects will meet with the lifestyle coach 25-27 times throughout the duration of the study.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PCCM
Description: Subjects will remain in their assigned treatment condition for 24 months.
Study: NCT00224445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Truvada
Description: Truvada (emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg tablet) administered orally once daily (QD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir
Description: Atazanavir 300 mg (given as two 150-mg capsules) administered orally QD
Study: NCT03425877

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rest
Description: At this stage, the HR and GSR signals will be recorded during a period of rest of 10 minutes. The subjects wear a pair of headphone for reducing the environmental sound noise. Through the headphones a sound indicates to the subject when recording starts and stops. Two separate recording of 5 minutes are performed, the first is performed while keeping eyes closed The two session are presented randomly to each different subject in order to prevent a bias due to order effect .

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rest
Description: At this stage, the HR and GSR signals will be recorded during a period of rest of 10 minutes. The subjects wear a pair of headphone for reducing the environmental sound noise. Through the headphones a sound indicates to the subject when recording starts and stops. Two separate recording of 5 minutes are performed, the first is performed while keeping eyes closed The two session are presented randomly to each different subject in order to prevent a bias due to order effect .

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rest
Description: At this stage, the HR and GSR signals will be recorded during a period of rest of 10 minutes. The subjects wear a pair of headphone for reducing the environmental sound noise. Through the headphones a sound indicates to the subject when recording starts and stops. Two separate recording of 5 minutes are performed, the first is performed while keeping eyes closed The two session are presented randomly to each different subject in order to prevent a bias due to order effect .
Study: NCT02248038

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open surgery
Description: Patients in this arm undergo radical resection of colon cancer in open surgery.Open surgery is a conventional technique for colorectal cancer patients.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic surgery
Description: Patients in this arm undergo radical resection of colon cancer in laparoscopic surgery.Laparoscopic surgery is a new and minimum invasive technique for colorectal cancer patients.
Study: NCT04174976

Intervention type: PROCEDURE
Intervention: wall hernia repair
Description: Wall hernia repair with mesh
Study: NCT03776097

Intervention type: OTHER
Intervention: observational study
Description: Observational study
Study: NCT04432285

Intervention type: DEVICE
Intervention: DBS-device, implanted in GPi bilaterally
Description: Chronic/continuous bilateral GPi-DBS

Intervention type: DRUG
Intervention: Botulinum toxin
Description: Repeated intramuscular injections at regular intervals of around 3 months
Study: NCT00476554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sapacitabine
Description: Sapacitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sapacitabine
Description: Sapacitabine
Study: NCT03317886

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pancreaticoduodenectomy
Description: pancreaticoduodenectomy for pancreatic ductal adenocarcinoma
Study: NCT03513315

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Implementation of Community-based Home Heat Bundle
Description: This community-based intervention include a set of educational materials to increase awareness about heat-related illness and prevention with the intention of reducing the incidence of heat-related and reducing mortality associated with heat-related illness. Materials used in this intervention will include posters, brochures, in-person training, and SMS messaging.
Study: NCT01970215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TA-8995
Study: NCT00422981

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AL-108
Description: 5 mg QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AL-108
Description: 15 mg BID
Study: NCT01970215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TA-8995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TA-8995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TA-8995

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TA-8995
Study: NCT00422981

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01970215

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TA-8995
Study: NCT01682863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QVA149
Description: QVA149 will be supplied in a capsule form in blister packs for use in the Novartis Concept1 SDDPI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QVA149
Description: QVA149 will be supplied in a capsule form in blister packs for use in the Novartis Concept1 SDDPI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: QAB149
Description: QAB149 and matching placebo will be supplied in capsule form in blister packs for use in the Novartis Concept1 SDDPI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: To mimic QAB149
Study: NCT03080415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combined Therapy SOF and DCV
Description: 1 whole or half tablet sofosbuvir and 1 whole or half tablet daclatasvir per day~SOF dosage: 400 mg/day for greater than 45 kg weight patients; 200 mg/day for 17 kg to 45 kg patients~DCV dosage: 60 mg/day for greater than 45 kg weight patients; 30 mg for 17 kg to 45 kg patients
Study: NCT05854888

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Perineal Massage and Warm Compresses (PeMWaC)
Description: Perineal Massage was performed in the II Hodge Plan, between maternal contractions and regardless of maternal position. Warm Compresses were applied by the midwife between Hodge plans III and IV, during pushing and regardless of maternal position.
Study: NCT01970215

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TA-8995 0mg (placebo)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TA-8995 0mg (placebo)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TA-8995 0mg (placebo)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Statin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Statin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Statin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Statin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Statin
Study: NCT03485339

Intervention type: DIAGNOSTIC_TEST
Intervention: genome testing
Description: blood sampling via venipuncture

Intervention type: DIAGNOSTIC_TEST
Intervention: genome testing
Description: blood sampling via venipuncture

Intervention type: DIAGNOSTIC_TEST
Intervention: genome testing
Description: blood sampling via venipuncture
Study: NCT05854888

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control Group (Hands-on)
Description: The midwife placed the index, middle, and little fingers of the non-dominant hand together on the child's occiput, with the palm facing the anterior region of the perineum, when the child's head was crowning. In this way, the expulsion was controlled, maintaining the flexion of the head. Simultaneously, the dominant hand was flattened and placed on the posterior region of the perineum, with the index finger and thumb, forming a U, exerting pressure on the posterior region of the perineum during the crowning process. During the birth of the shoulders and the rest of the body, the dominant hand was kept in place, protecting the posterior region of the perineum.
Study: NCT01831453

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: omega-3
Description: polyunsaturated fatty acids(PUFAs) 1 gram three times per day for 6 months
Study: NCT00865696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirtazapine 15 mg tablets, single dose
Description: A: Experimental Subjects received Purepac formulated products under fasting conditions
Study: NCT03513315

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Regular Community Healthcare provision
Description: The community will get regular community health workers visit without the focus community mobilization and education on heat-related illnesses.
Study: NCT01831453

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: soft gelatinous capsules filled with isopropylmyristate oil
Study: NCT01386151

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Keratinocyte Growth factor
Description: KGF will be administered intravenously in a 'collapsed dose' regime of 180ug/kg on day 0 and day 11

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline placebo
Description: Normal (0.9%) saline will be used as a placebo.
Study: NCT02757365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin
Study: NCT00865696

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: REMERON® 15 mg tablets, single dose
Description: B: Active comparator Subjects received Organon Inc. formulated products under fasting conditions
Study: NCT03045315

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IVF Procedure
Study: NCT02757365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Study: NCT00288054

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Cohorts 1 and 2: 400 mg/m2 (initial dose) 2 hour IV infusion on Day 1, Cycle 1 only.~250 mg/m2, 1 hour IV infusion on Days 8 , 15 and 22 during Cycle 1. 250 mg/m2 (subsequent doses), 1 hour IV infusion on Days 1, 8 , 15 and 22 during subsequent cycles.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Cohorts 1 and 2: 400 mg/m2 (initial dose) 2 hour IV infusion on Day 1, Cycle 1 only.~250 mg/m2, 1 hour IV infusion on Days 8 , 15 and 22 during Cycle 1. 250 mg/m2 (subsequent doses), 1 hour IV infusion on Days 1, 8 , 15 and 22 during subsequent cycles.
Study: NCT00469209

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trisenox (Arsenic Trioxide)
Description: 0.25 mg/kg by vein over 2 hours, once a day for 7 days (Days -9 to -3).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trisenox (Arsenic Trioxide)
Description: 0.25 mg/kg by vein over 2 hours, once a day for 7 days (Days -9 to -3).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trisenox (Arsenic Trioxide)
Description: 0.25 mg/kg by vein over 2 hours, once a day for 7 days (Days -9 to -3).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Velcade (Bortezomib)
Description: Arm 1 (Level 1):~1.0 mg/m\^2 intravenous (IV) push on Days -9, -6, and -3. An IV push takes a short period of time (less than 1 minute).~Arm 2 (Level 2):~1.5 mg/m\^2 intravenous (IV) push on Days -9, -6, and -3. An IV push takes a short period of time (less than 1 minute).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Velcade (Bortezomib)
Description: Arm 1 (Level 1):~1.0 mg/m\^2 intravenous (IV) push on Days -9, -6, and -3. An IV push takes a short period of time (less than 1 minute).~Arm 2 (Level 2):~1.5 mg/m\^2 intravenous (IV) push on Days -9, -6, and -3. An IV push takes a short period of time (less than 1 minute).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melphalan
Description: 100 mg/m2 by vein days -4,-3, over 30 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melphalan
Description: 100 mg/m2 by vein days -4,-3, over 30 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melphalan
Description: 100 mg/m2 by vein days -4,-3, over 30 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin C (Ascorbic Acid)
Description: 1000 mg once a day through the vein for 7 days.
Study: NCT00288054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Cohort 2 ONLY: 20 mg/m2 IV over 15 - 30 minutes on Days 8, 15 and 22 of Cycle 1. Concurrent with RT and cetuximab starting at Week 2.~20 mg/m2 IV over 15 - 30 minutes on Days 1, 8, 15 and 22 of Cycle 2.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Radiation therapy should begin on Day 8 of Cycle 1 and continue through the end of Cycle 2. Refer to Section 12.1 for Radiation Therapy Review.~RT prescription should be PTV (GTV + 2-cm margins on CT scan) to 6,480 cGy in 36 fractions given 5 days a week, 180 cGy per day. The dose is prescribed to the isocenter. The entire treatment should be planned prior to starting treatment to ensure that the plan meets protocol specifications.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Radiation therapy should begin on Day 8 of Cycle 1 and continue through the end of Cycle 2. Refer to Section 12.1 for Radiation Therapy Review.~RT prescription should be PTV (GTV + 2-cm margins on CT scan) to 6,480 cGy in 36 fractions given 5 days a week, 180 cGy per day. The dose is prescribed to the isocenter. The entire treatment should be planned prior to starting treatment to ensure that the plan meets protocol specifications.
Study: NCT00469209

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin C (Ascorbic Acid)
Description: 1000 mg once a day through the vein for 7 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin C (Ascorbic Acid)
Description: 1000 mg once a day through the vein for 7 days.
Study: NCT00531492

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TK as soon as possible within 24 hours after birth
Description: Start TK as soon as possible within 24 hours after birth

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional care
Description: Start conventional care (At first use incubator, and start TK when the infants and mother are completely settled and ready)
Study: NCT00915538

Intervention type: DRUG
Group type: OTHER
Intervention: pMDI budesonide/formotrol 160/4.5 is in group 1
Description: The asthmatic subjects will receive budesonide/formoterol pMDI 160/4.5 pMDI 2 inhalations used in conventional fashion, and have pulmonary function measured over 12 hours who are expected to show bronchodilation.
Study: NCT00286299

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic high-intensity interval training (AIT)
Description: The AIT group trains 4x4 minute interval training on a treadmill at 85-95 % HRpeak interspersed with 3 minutes of active resting periods at a work load corresponding to 70% HRpeak between each interval. All training sessions are monitored and start with a 6 minute warm-up and end with a 5 minute cool-down period at a work load corresponding to 70% HRpeak. Intervals are performed walking or running on a treadmill with a minimum of 5% inclination, 3 times per week for 8 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Computer game training (CG)
Description: The CG spend the same amount of time (36 minutes), training to improve their ability in the computer game, Tetris. Tetris is a game where small shapes called Tetraminoes fall from the top of the Playfield to the bottom. Players must rotate the Tetraminoes as they fall and fit them together to complete lines. When the player fills an entire line with blocks, that line is removed from the screen. If the player cannot complete lines, the blocks will eventually rise past the top of the screen, and the game ends.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maximal strength training
Description: Training starts with a 10 minute warm-up on the treadmill. Maximal strength training is then performed in an inclined leg press machine. The subject lifts 4 maximal repetitions that are repeated 4 times after a 2 minute rest period. Subjects are instructed to lift the weight with an intention of maximal mobilization of force. Training load is increased each time the subject manage to perform 4x4 maximal repetitions. Training is carried out 3 times per week in 8 weeks.
Study: NCT00695409

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carmustine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ASCT
Description: Undergo autologous peripheral blood stem cell transplant

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: yttrium Y 90 ibritumomab tiuxetan
Description: Given IV
Study: NCT04218422

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Battlefield Acupuncture
Description: Acupuncture at 5 points on the ears

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Acupuncture
Description: Sham acupuncture in 2 points for liver and 1 point for stomach
Study: NCT01529502

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Red blood Cells auto-transfusion
Description: Withdrawal from 14 overweight volunteers of one unit of red blood cells and auto-transfusion after 3 days storage time. The same 14 subjects will be included in every arm of the study.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Red blood Cells auto-transfusion
Description: Withdrawal from the same 14 overweight volunteers of one unit of red blood cells and auto-transfusion after 40 days storage time.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Red blood Cells auto-transfusion
Description: Withdrawal from the same 14 overweight volunteers of one unit of red blood cells and auto-transfusion after 40 days storage time.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Nitric Oxide (iNO) administration
Description: Subjects will breath iNO (80ppm) for 10 minutes before, during and for one hour after the autologous old-blood transfusion.
Study: NCT02687997

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: poligraphy
Description: Sleep study
Study: NCT04649658

Intervention type: BEHAVIORAL
Intervention: Prone position
Description: Prone position maintained at least 3 hours/day